SBFM
Sunshine Biopharma, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
1.17
▲ 0.01 (0.86%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.19
Prev close
1.16
Day high
1.17
Day low
1.14
Volume
96.61K
Market cap
—
P/E (TTM)
—
52W range
1.03 – 24.30
Trailing performance
Returnvs SPY
1W
+0.87%
+2.2%
1M
-32.16%
-35.9%
3M
-77.52%
-80.6%
6M
-90.17%
-101.2%
YTD
-90.57%
-102.9%
1Y
-91.88%
-111.9%
3Y
-99.99%
-174.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on SBFM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $36.31M | $34.87M | $24.09M | $4.35M | +4.1% |
| Operating revenue | $36.31M | $34.87M | $24.09M | $4.35M | +4.1% |
| Cost of revenue | $24.05M | $24.20M | $15.75M | $2.65M | -0.6% |
| Gross profit | $12.26M | $10.67M | $8.34M | $1.70M | +14.9% |
| Research & development | $604.31K | $933.90K | $1.86M | $811.86K | -35.3% |
| Selling, general & admin | $15.33M | $14.94M | $10.83M | $9.48M | +2.6% |
| Total operating expense | $16.73M | $16.48M | $13.12M | $10.37M | +1.5% |
| Operating income | -$4.48M | -$5.81M | -$4.79M | -$8.67M | +22.9% |
| Net interest income | $280.90K | $487.23K | $674.67K | $479.24K | -42.3% |
| Pre-tax income | -$5.95M | -$5.37M | -$4.11M | -$26.51M | -10.9% |
| Tax provision | $21.61K | -$234.86K | $395.17K | $233.30K | +109.2% |
| Net income | -$5.98M | -$5.13M | -$4.51M | -$26.74M | -16.4% |
| Net income to common | -$5.98M | -$5.13M | -$4.51M | -$26.74M | -16.4% |
| Basic EPS | -14.40 | -73.20 | -3,513.60 | -23,688.61 | +80.3% |
| Diluted EPS | -14.40 | -73.20 | -3,513.60 | -23,688.61 | +80.3% |
| EBIT | -$5.95M | -$5.36M | -$3.97M | -$26.47M | -11.1% |
| EBITDA | -$5.62M | -$5.14M | -$3.82M | -$26.45M | -9.4% |
| Basic shares | 415.71K | 70.17K | 1.28K | 1.13K | +492.4% |
| Diluted shares | 415.71K | 70.17K | 1.28K | 1.13K | +492.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.12M | $9.69M | $16.29M | $21.83M | — | -5.8% |
| Cash & short-term investments | $9.12M | $9.69M | $16.29M | $21.83M | — | -5.8% |
| Accounts receivable | $3.46M | $3.87M | $2.55M | $1.91M | — | -10.6% |
| Inventory | $13.47M | $11.28M | $5.73M | $3.29M | — | +19.5% |
| Total current assets | $26.85M | $25.97M | $24.89M | $27.31M | — | +3.4% |
| Property, plant & equipment | $1.32M | $1.48M | $1.01M | $1.15M | — | -11.2% |
| Goodwill & intangibles | $1.89M | $3.02M | $1.44M | $776.86K | — | -37.4% |
| Total assets | $30.08M | $30.56M | $27.35M | $29.24M | — | -1.6% |
| Total current liabilities | $6.44M | $6.31M | $5.55M | $6.93M | — | +2.0% |
| Current debt | — | — | — | $3.63M | — | — |
| Long-term debt | — | — | — | — | $1.90M | — |
| Total debt | $812.42K | $952.48K | $657.71K | $765.26K | — | -14.7% |
| Total liabilities | $7.04M | $7.06M | $6.14M | $7.62M | — | -0.3% |
| Retained earnings | -$75.02M | -$69.04M | -$63.91M | -$59.40M | — | -8.7% |
| Shareholder equity | $23.04M | $23.50M | $21.21M | $21.63M | — | -2.0% |
| Working capital | $20.41M | $19.65M | $19.34M | $20.38M | — | +3.9% |
| Net tangible assets | $21.15M | $20.48M | $19.76M | $20.85M | — | +3.3% |
| Shares issued | 490.59K | 258.01K | 1.40K | 1.13K | — | +90.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$5.98M | -$5.13M | -$4.51M | -$26.74M | -16.4% |
| Depreciation & amortisation | $332.07K | $223.53K | $149.15K | $25.16K | +48.6% |
| Change in working capital | -$1.45M | -$5.37M | -$4.42M | $3.15M | +73.1% |
| Operating cash flow | -$5.33M | -$12.52M | -$8.78M | -$5.25M | +57.4% |
| Capital expenditure | -$836.31K | -$1.98M | -$788.10K | -$305.00K | +57.7% |
| Investing cash flow | -$836.31K | -$1.98M | -$656.15K | -$14.62M | +57.7% |
| Share buybacks | $0 | -$3.14M | -$541.14K | -$99.00K | +100.0% |
| Financing cash flow | $4.75M | $8.94M | $3.43M | $39.47M | -46.9% |
| Free cash flow | -$6.17M | -$14.50M | -$9.56M | -$5.55M | +57.5% |
| End cash position | $9.12M | $9.69M | $16.29M | $21.83M | -5.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $8.09M | $8.58M | $9.42M | $9.41M | $8.90M | -5.7% |
| Operating revenue | $8.09M | $8.58M | $9.42M | $9.41M | $8.90M | -5.7% |
| Cost of revenue | $5.91M | $5.55M | $6.34M | $5.99M | $6.17M | +6.5% |
| Gross profit | $2.18M | $3.03M | $3.07M | $3.42M | $2.73M | -28.0% |
| Research & development | $31.72K | $73.50K | $119.30K | $196.23K | $215.28K | -56.8% |
| Selling, general & admin | $3.34M | $4.39M | $3.27M | $4.03M | $3.64M | -23.9% |
| Total operating expense | $3.58M | $4.69M | $3.61M | $4.42M | $4.03M | -23.7% |
| Operating income | -$1.40M | -$1.66M | -$531.96K | -$992.85K | -$1.30M | +15.8% |
| Net interest income | $48.43K | $57.47K | $75.35K | $72.72K | $75.37K | -15.7% |
| Pre-tax income | -$1.24M | -$1.73M | -$1.02M | -$1.98M | -$1.22M | +28.2% |
| Tax provision | $0 | $408.37K | -$137.44K | -$209.17K | -$40.16K | -100.0% |
| Net income | -$1.24M | -$2.14M | -$883.82K | -$1.77M | -$1.18M | +41.9% |
| Net income to common | -$1.24M | -$2.14M | -$883.82K | -$1.77M | -$1.18M | +41.9% |
| Basic EPS | -2.50 | — | -1.90 | -3.90 | -4.40 | — |
| Diluted EPS | -2.50 | — | -1.90 | -3.90 | -4.40 | — |
| EBIT | -$1.40M | -$1.73M | -$1.02M | -$1.98M | -$1.30M | +19.4% |
| EBITDA | -$1.32M | -$1.63M | -$925.10K | -$1.91M | -$1.23M | +19.3% |
| Basic shares | 490.59K | — | 455.59K | 449.61K | 270.33K | — |
| Diluted shares | 490.59K | — | 455.59K | 449.61K | 270.33K | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.91M | $9.12M | $9.31M | $10.31M | $8.12M | -24.2% |
| Cash & short-term investments | $6.91M | $9.12M | $9.31M | $10.31M | $8.12M | -24.2% |
| Accounts receivable | $4.01M | $3.46M | $4.16M | $3.59M | $3.45M | +15.9% |
| Inventory | $13.17M | $13.47M | $14.06M | $13.02M | $11.86M | -2.3% |
| Total current assets | $24.78M | $26.85M | $27.97M | $27.85M | $24.48M | -7.7% |
| Property, plant & equipment | $1.23M | $1.32M | $1.42M | $1.53M | $1.42M | -6.6% |
| Goodwill & intangibles | $1.92M | $1.89M | $2.01M | $2.49M | $3.19M | +1.5% |
| Total assets | $27.93M | $30.08M | $31.49M | $31.97M | $29.19M | -7.1% |
| Total current liabilities | $5.88M | $6.44M | $6.65M | $5.57M | $5.76M | -8.8% |
| Total debt | $744.84K | $812.42K | $854.76K | $929.03K | $936.18K | -8.3% |
| Total liabilities | $6.41M | $7.04M | $7.29M | $6.28M | $6.48M | -8.9% |
| Retained earnings | -$76.26M | -$75.02M | -$72.87M | -$71.99M | -$70.22M | -1.7% |
| Shareholder equity | $21.52M | $23.04M | $24.20M | $25.68M | $22.70M | -6.6% |
| Working capital | $18.91M | $20.41M | $21.32M | $22.28M | $18.72M | -7.4% |
| Net tangible assets | $19.60M | $21.15M | $22.19M | $23.19M | $19.51M | -7.3% |
| Shares issued | 490.59K | 490.59K | 455.59K | 455.59K | 270.75K | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$1.24M | -$2.14M | -$883.82K | -$1.77M | -$1.18M | — | +41.9% |
| Depreciation & amortisation | $76.86K | $98.58K | $96.16K | $72.53K | $64.79K | — | -22.0% |
| Change in working capital | -$905.09K | $301.57K | -$512.07K | -$655.77K | -$580.02K | — | -400.1% |
| Operating cash flow | -$2.07M | -$1.62M | -$727.80K | -$1.29M | -$1.70M | — | -28.2% |
| Capital expenditure | -$104.52K | -$39.96K | -$34.14K | -$550.19K | -$212.02K | — | -161.6% |
| Investing cash flow | -$104.52K | -$50.21K | -$118.30K | -$455.79K | -$212.02K | — | -108.2% |
| Share buybacks | — | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $0 | $724.50K | $75.54K | $3.59M | $355.30K | — | -100.0% |
| Free cash flow | -$2.18M | -$1.66M | -$761.94K | -$1.84M | -$1.91M | — | -31.4% |
| End cash position | $6.91M | $9.12M | $9.31M | $10.31M | $8.12M | — | -24.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.17
-0.34% from price
SMA 20
1.24
-6.34% from price
SMA 50
1.71
-32.25% from price
SMA 100
4.65
-74.84% from price
SMA 200
8.80
-86.82% from price
EMA 12
1.21
-3.09% from price
EMA 26
1.42
-17.67% from price
EMA 50
2.19
-46.56% from price
RSI (14)
30.4
Neutral
MACD (12,26,9)
-0.21
Hist 0.04
ATR (14)
0.13
11.48% of price
Realised vol 30D
79.8%
Annualised
Bollinger upper
1.45
20, 2σ
Bollinger lower
1.03
20, 2σ
50 / 200 cross
Death
1.71 vs 8.80
Trend bias
Below 200
-86.82%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
79.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-94.9%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.13
11.48% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
ACCESS Newswire · 4d ago
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
Benzinga · 4d ago
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
ACCESS Newswire · 16d ago
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
ACCESS Newswire · 19d ago
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval
Benzinga · 19d ago
Sunshine Biopharma Receives Health Canada Approval for Generic Ondansetron to Treat Chemotherapy-Induced Nausea
MT Newswires · 26d ago
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
ACCESS Newswire · 26d ago
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
ACCESS Newswire · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.